Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses HRTX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named HRTX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Mark Hensley | $372,212 | $0 | $1,210,000 | $2,527,680 | $187,108 | $0 | $10,500 | $4,307,500 |
| Executive Vice President, Chief Operating Officer | ||||||||
| Craig Collard | 689,431 | 0 | 946,254 | 1,352,917 | 517,189 | 0 | 10,500 | 3,516,291 |
| Chief Executive Officer | ||||||||
| William Forbes | 609,881 | 0 | 318,087 | 454,788 | 305,009 | 0 | 0 | 1,687,765 |
| Executive Vice President, Chief Development Officer | ||||||||
| Ira Duarte | 559,803 | 0 | 318,087 | 454,788 | 287,500 | 0 | 10,500 | 1,630,678 |
| Executive Vice President, Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Mark Hensley | $4,307,500 | — | — | — |
| Craig Collard | 3,516,291 | 1,424,811 | 10,775,818 | +2,091,480 |
| William Forbes | 1,687,765 | 1,536,130 | 1,458,106 | +151,635 |
| Ira Duarte | 1,630,678 | 1,424,811 | 1,534,873 | +205,867 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| William Forbes | EVP, Chief Development Officer | 2026-04-30 | D | 11,694 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| William Forbes | EVP, Chief Development Officer | 2026-04-30 | A | 11,770 | — | — | Common | Form 4 ↗ |
| Mark Hensley | Chief Operating Officer | 2026-04-30 | D | 11,770 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-04-30 | D | 11,694 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Collard | Director | 2026-04-30 | D | 50,021 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Mark Hensley | Chief Operating Officer | 2026-04-30 | A | 11,770 | — | — | Common | Form 4 ↗ |
| William Forbes | EVP, Chief Development Officer | 2026-04-30 | A | 11,694 | — | — | Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-04-30 | A | 13,535 | — | — | Common | Form 4 ↗ |
| Craig Collard | Director | 2026-04-30 | A | 34,789 | — | — | Common | Form 4 ↗ |
| William Forbes | EVP, Chief Development Officer | 2026-04-30 | D | 11,770 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-04-30 | A | 11,694 | — | — | Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-04-30 | D | 13,535 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Collard | Director | 2026-04-30 | D | 34,789 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Collard | Director | 2026-04-30 | A | 50,021 | — | — | Common | Form 4 ↗ |
| Mark Hensley | Chief Operating Officer | 2026-05-06 | A | 125,000 | — | — | Common | Form 4 ↗ |
| Mark Hensley | Chief Operating Officer | 2026-05-06 | D | 125,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Forbes | EVP, Chief Development Officer | 2026-06-06 | A | 12,500 | — | — | Common | Form 4 ↗ |
| William Forbes | EVP, Chief Development Officer | 2026-06-06 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-06-16 | A | 12,500 | — | — | Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-06-16 | D | 3,555 | 0 | 1,351 | Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-06-16 | D | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-07-19 | D | 1,101 | 0 | 517 | Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-07-19 | A | 3,874 | — | — | Common | Form 4 ↗ |
| Ira Duarte | EVP, Chief Financial Officer | 2026-07-19 | D | 3,874 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Forbes | EVP, Chief Development Officer | 2026-07-19 | D | 3,874 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Forbes | EVP, Chief Development Officer | 2026-07-19 | A | 3,874 | — | — | Common | Form 4 ↗ |
| Craig Collard | Director | 2026-07-19 | D | 13,797 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Craig Collard | Director | 2026-07-19 | A | 13,797 | — | — | Common | Form 4 ↗ |
| William Forbes | EVP, Chief Development Officer | 2026-07-19 | D | 1,101 | 0 | 517 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| William Forbes | RSU | 2025-01-31 | — | — | 187,110 | — | $318,087 |
| Craig Collard | RSU | 2025-01-31 | — | — | 556,620 | — | 946,254 |
| Mark Hensley | OPTION | 2025-04-28 | — | — | 500,000 | — | 827,680 |
| Ira Duarte | RSU | 2025-01-31 | — | — | 187,110 | — | 318,087 |
| Ira Duarte | OPTION | 2025-01-31 | — | — | 374,220 | — | 454,788 |
| William Forbes | OPTION | 2025-01-31 | — | — | 374,220 | — | 454,788 |
| Mark Hensley | OPTION | 2025-04-28 | — | — | 900,000 | — | 1,700,000 |
| Mark Hensley | RSU | 2025-05-06 | — | — | 500,000 | — | 1,210,000 |
| Craig Collard | OPTION | 2025-01-31 | — | — | 1,113,240 | — | 1,352,917 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| William Forbes | $318,087 | $0 | $454,788 | 0.0% |
| Craig Collard | 946,254 | 0 | 1,352,917 | 0.0% |
| Mark Hensley | 1,210,000 | 0 | 2,527,680 | 0.0% |
| Ira Duarte | 318,087 | 0 | 454,788 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Craig Collard | RSU | 452,254 | — | $587,930 |
| Craig Collard | Option | 112,358 | 1.78 | — |
| Ira Duarte | RSU | 34,869 | — | 45,330 |
| Craig Collard | RSU | 125,000 | — | 162,500 |
| Mark Hensley | RSU | 500,000 | — | 650,000 |
| William Forbes | Option | 288,461 | 1.7 | — |
| Ira Duarte | RSU | 25,000 | — | 32,500 |
| Mark Hensley | Option | 500,000 | 2.33 | — |
| William Forbes | RSU | 152,027 | — | 197,635 |
| Craig Collard | RSU | 124,172 | — | 161,424 |
| Craig Collard | Option | 689,845 | 2.09 | — |
| Craig Collard | Option | 858,122 | 1.7 | — |
| Ira Duarte | Option | 193,716 | 2.09 | — |
| Ira Duarte | Option | 288,461 | 1.7 | — |
| William Forbes | RSU | 25,000 | — | 32,500 |
| Craig Collard | RSU | 11,837 | — | 15,388 |
| Ira Duarte | RSU | 152,027 | — | 197,635 |
| William Forbes | Option | 187,500 | 1.11 | — |
| William Forbes | RSU | 34,869 | — | 45,330 |
| William Forbes | Option | 193,716 | 2.09 | — |
| Craig Collard | RSU | 1,887,642 | — | 2,453,934 |
| Ira Duarte | Option | 300,000 | 1.21 | — |
Our Named Executive Officer compensation program is thoughtfully designed to attract, motivate and retain high-caliber executives who drive our success, to promote teamwork in a straightforward and effective way, and to emphasize the executives' shared responsibility for our overall success. We structure our Named Executive Officer compensation program to include significant performance metrics that are aligned with our business strategy and shareholder value creation.
| CEO STI target (% of salary) | 75% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia, Inc. |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-11 | 77,315,474 | 12,117,861 | 2,378,521 | 86.45% | Passed |
| 2024 | 2024-06-13 | 72,711,988 | 14,427,205 | 2,329,798 | 83.44% | Passed |
| 2023 | 2023-06-08 | 69,340,148 | 1,730,470 | 406,336 | 97.57% | Passed |
| 2022 | 2022-05-24 | 49,881,191 | 16,852,563 | 187,524 | 74.75% | Passed |
| 2021 | 2021-06-17 | 62,482,925 | 4,003,746 | 173,538 | 93.98% | Passed |
| 2020 | 2020-06-17 | 60,705,865 | 3,569,221 | 182,037 | 94.45% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-11 | 86.45%a |
| 2024 | 2024-06-13 | 83.44%b |
| 2023 | 2023-06-08 | 97.57%c |
a. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of this proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will have no effect on the outcome of this proposal.”.
c. Approved under the standard stated in the filing — “Accordingly, assuming this proposal is deemed to be a "non-routine" matter under NYSE rules as we have been advised by the NYSE, abstentions and broker non-votes will have no effect on this proposal.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 13.08 : 1 |
|---|---|
| CEO total compensation | $3,516,291 |
| Median employee compensation | $268,890 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Tom CusackIndependent · Nominating/Governance · Newly elected | $10,258 | $177,179 | $41,667 | $0 | $0 | $229,104 |
| Adam MorganIndependent · Board Chair | 85,556 | 43,629 | 30,515 | 0 | 0 | 159,700 |
| Craig JohnsonIndependent · Audit (Chair) · Compensation | 77,500 | 43,629 | 30,515 | 0 | 0 | 151,644 |
| Sharmila DissanaikeIndependent · Compensation (Chair) · Nominating/Governance | 70,000 | 43,629 | 30,515 | 0 | 0 | 144,144 |
| Christian WaageIndependent · Audit · Nominating/Governance (Chair) | 70,000 | 43,629 | 30,515 | 0 | 0 | 144,144 |
| Michael KasetaIndependent · Audit · Compensation | 61,325 | 43,629 | 30,515 | 0 | 0 | 135,469 |
| Susan RodriguezIndependent · Departed during FY | 31,806 | 43,629 | 30,515 | 0 | 0 | 105,950 |
| Craig CollardEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | — |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $406,445 |
| Equity awards (grant-date value) | $438,953 |
| All other compensation | $0 |
| Total cost of the board | $845,398 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Heron Therapeutics, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Heron Therapeutics, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Ocular Therapeutics | 2025 | Pravin Dugel | $819,200 | $18,608,000 | $15,567,000 | $0 | $35,946,958 |
| 2 | Harrow | 2025 | Mark Baum | 754,910 | 22,294,873 | 0 | 542,491 | 23,606,274 |
| 3 | ANI Pharmaceuticals | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 4 | Travere Therapeutics | 2025 | Eric Dube | 854,250 | 3,314,520 | 3,309,384 | 964,125 | 8,457,151 |
| 5 | Sage Therapeutics | 2024 | Barry Greene | 830,712 | 3,164,364 | 2,669,263 | 431,970 | 7,112,589 |
| 6 | Phantom Pharmaceuticals | 2025 | Steven Basta | 525,000 | 1,986,600 | 3,983,144 | 455,701 | 6,968,070 |
| 7 | Akebia Therapeutics | 2025 | John Butler | 864,010 | 2,164,338 | 2,024,798 | 580,973 | 5,652,339 |
| 8 | Innoviva | 2025 | Pavel Raifeld | 600,000 | 2,649,982 | 1,748,882 | 0 | 5,400,197 |
| 9 | Xeris Biopharma Holdings | 2025 | John Shannon | 742,334 | 2,848,000 | 838,615 | 607,971 | 5,042,584 |
| 10 | Rigel Pharmaceuticals | 2025 | Raul Rodriguez | 787,405 | 951,327 | 2,241,570 | 634,649 | 4,658,805 |
| 11 | Y-mAbs Therapeutics | 2024 | Michael Rossi | 705,600 | 1,170,732 | 2,288,662 | 392,596 | 4,557,590 |
| 12 | UroGen Pharma | 2025 | Elizabeth Barrett | 855,590 | 2,122,211 | 0 | 516,263 | 4,310,624 |
| 13 | Vanda Pharmaceuticals | 2025 | Mihael Polymeropoulos | 965,655 | 2,007,000 | 0 | 834,326 | 3,851,468 |
| 14 | Lexicon Pharmaceuticals | 2025 | Michael Exton | 650,576 | 1,049,304 | 1,355,231 | 0 | 3,553,953 |
| 15 | Esperion Therapeutics | 2025 | Sheldon Koenig | 770,833 | 1,260,000 | 847,929 | 639,375 | 3,535,512 |
| 16 | Heron Therapeutics, Inc. | 2025 | Craig Collard | 689,431 | 946,254 | 1,352,917 | 517,189 | 3,516,291 |
| 17 | Coherus BioSciences | 2025 | Dennis Lanfear | 1,026,545 | 0 | 828,130 | 869,295 | 2,736,874 |
| 18 | OptiNose | 2023 | Ramy Mahmoud | 646,994 | 637,075 | 656,245 | 454,740 | 2,414,265 |
| 19 | Collegium Pharmaceuticals | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
| — | G1 Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Heron Therapeutics, Inc. | 100% | Options 67 · RSU 33 | not disclosed | Compensia, Inc. |
| Akebia Therapeutics | 90% | Options 50 · RSU 25 · MSU 25 | No | Pearl Meyer |
| ANI Pharmaceuticals | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Coherus BioSciences | not disclosed | Options 100 | not disclosed | Aon |
| Collegium Pharmaceuticals | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Esperion Therapeutics | 110% | not disclosed | not disclosed | not disclosed |
| G1 Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Harrow | 100% | not disclosed | No | Mercer, Inc. |
| Innoviva | 105% | not disclosed | not disclosed | Meridian |
| Lexicon Pharmaceuticals | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Ocular Therapeutics | 145% | not disclosed | No | Aon |
| OptiNose | not disclosed | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| Phantom Pharmaceuticals | 124% | not disclosed | No | Pay Governance LLC |
| Rigel Pharmaceuticals | 124% | Options 75 · RSU 25 | No | Pearl Meyer |
| Sage Therapeutics | 80% | not disclosed | Yes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology Index | Alpine Rewards |
| Travere Therapeutics | 150% | not disclosed | No | Aon |
| UroGen Pharma | 80% | RSU 50 · PSU 50 | No | Compensia, Inc. |
| Vanda Pharmaceuticals | 108% | not disclosed | Yes — Relative TSR | Willis Towers Watson |
| Xeris Biopharma Holdings | 125% | not disclosed | not disclosed | Aon Consulting, Inc. |
| Y-mAbs Therapeutics | 85.6% | PSU 34 · Options 33 · RSU 33 | No | Aon's Human Capital Solutions practice (division of Aon plc) |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Mark Hensley | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Executive Compensation Tables”. As printed: 4,307,500. Filing ↗machine: span 825030–825039 |
| 2 | Section 01, Craig Collard | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Executive Compensation Tables”. As printed: 3,516,291. Filing ↗machine: span 728212–728221 |
| 3 | Section 01, William Forbes | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Executive Compensation Tables”. As printed: 1,687,765. Filing ↗machine: span 792749–792758 |
| 4 | Section 01, Ira Duarte | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Executive Compensation Tables”. As printed: 1,630,678. Filing ↗machine: span 760485–760494 |
| 5 | Section 03, William Forbes RSU | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r8 · c9 · span 786533–786540 |
| 6 | Section 03, Craig Collard RSU | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r2 · c9 · span 721995–722002 |
| 7 | Section 03, Mark Hensley OPTION | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r13 · c25 · span 990670–990677 |
| 8 | Section 03, Ira Duarte RSU | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r5 · c9 · span 754270–754277 |
| 9 | Section 03, Ira Duarte OPTION | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r5 · c13 · span 755824–755831 |
| 10 | Section 03, William Forbes OPTION | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r8 · c13 · span 788087–788094 |
| 11 | Section 03, Mark Hensley OPTION | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t21 · r14 · c25 · span 1001514–1001523 |
| 12 | Section 03, Mark Hensley RSU | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r11 · c9 · span 818811–818820 |
| 13 | Section 03, Craig Collard OPTION | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t20 · r2 · c13 · span 723549–723558 |
| 14 | Section 07, pay ratio | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “CEO Pay Ratio”. As printed: 13.08 : 1. Filing ↗ |
| 15 | Section 08, Tom Cusack | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Director Compensation”. As printed: 229,104. Filing ↗machine: t9 · r2 · c15 · span 324339–324346 |
| 16 | Section 08, Adam Morgan | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Director Compensation”. As printed: 159,700. Filing ↗machine: t9 · r6 · c15 · span 351694–351701 |
| 17 | Section 08, Craig Johnson | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Director Compensation”. As printed: 151,644. Filing ↗machine: t9 · r4 · c15 · span 338029–338036 |
| 18 | Section 08, Sharmila Dissanaike | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Director Compensation”. As printed: 144,144. Filing ↗ |
| 19 | Section 08, Christian Waage | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Director Compensation”. As printed: 144,144. Filing ↗machine: t9 · r8 · c15 · span 365525–365532 |
| 20 | Section 08, Michael Kaseta | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Director Compensation”. As printed: 135,469. Filing ↗machine: t9 · r5 · c15 · span 344863–344870 |
| 21 | Section 08, Susan Rodriguez | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Director Compensation”. As printed: 105,950. Filing ↗machine: t9 · r7 · c15 · span 358690–358697 |
| 22 | Section 08, Craig Collard | DEF 14A | 2026-04-30 | 0001193125-26-196306 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 02, William Forbes 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203344 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, William Forbes 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203344 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Mark Hensley 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203374 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Ira Duarte 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203272 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Craig Collard 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203196 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Mark Hensley 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203374 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, William Forbes 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203344 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Ira Duarte 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203272 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Craig Collard 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203196 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, William Forbes 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203344 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Ira Duarte 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203272 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Ira Duarte 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203272 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Craig Collard 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203196 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Craig Collard 2026-04-30 | Form 4 | 2026-05-04 | 0001193125-26-203196 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Mark Hensley 2026-05-06 | Form 4 | 2026-05-07 | 0001193125-26-211230 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Mark Hensley 2026-05-06 | Form 4 | 2026-05-07 | 0001193125-26-211230 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, William Forbes 2026-06-06 | Form 4 | 2026-06-08 | 0001193125-26-260931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, William Forbes 2026-06-06 | Form 4 | 2026-06-08 | 0001193125-26-260931 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Ira Duarte 2026-06-16 | Form 4 | 2026-06-17 | 0001193125-26-273552 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Ira Duarte 2026-06-16 | Form 4 | 2026-06-17 | 0001193125-26-273552 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Ira Duarte 2026-06-16 | Form 4 | 2026-06-17 | 0001193125-26-273552 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Ira Duarte 2026-07-19 | Form 4 | 2026-07-20 | 0001193125-26-308887 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Ira Duarte 2026-07-19 | Form 4 | 2026-07-20 | 0001193125-26-308887 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Ira Duarte 2026-07-19 | Form 4 | 2026-07-20 | 0001193125-26-308887 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, William Forbes 2026-07-19 | Form 4 | 2026-07-20 | 0001193125-26-308922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, William Forbes 2026-07-19 | Form 4 | 2026-07-20 | 0001193125-26-308922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Craig Collard 2026-07-19 | Form 4 | 2026-07-20 | 0001193125-26-308958 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Craig Collard 2026-07-19 | Form 4 | 2026-07-20 | 0001193125-26-308958 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, William Forbes 2026-07-19 | Form 4 | 2026-07-20 | 0001193125-26-308922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 06, 2026 vote | Form 8-K | 2026-06-16 | 0001193125-26-272388 | Item 5.07 · say-on-pay result. As reported: 86.45% (votes for as printed: 77,315,474). Filing ↗ |
| 53 | Section 06, 2024 vote | Form 8-K | 2024-06-18 | 0000950170-24-074952 | Item 5.07 · say-on-pay result. As reported: 83.44% (votes for as printed: 72,711,988). Filing ↗ |
| 54 | Section 06, 2023 vote | Form 8-K | 2023-06-12 | 0000950170-23-027374 | Item 5.07 · say-on-pay result. As reported: 97.57% (votes for as printed: 69,340,148). Filing ↗ |
| 55 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 56 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 57 | Section 09b board cost (computed) | Computed | — | computed | Cash 406,445 + equity 438,953 + all other 0 = 845,398, summed across the director compensation table rows.machine: formula: Σ = 845,398 |
| 58 | Ocular Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053176 | CEO total compensation as printed in Ocular Therapeutics's own proxy. As printed: 35,946,958. Filing ↗machine: t128 · r3 · c15 · span 574379–574389 |
| 59 | Harrow, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001493152-26-018912 | CEO total compensation as printed in Harrow's own proxy. As printed: 23,606,274. Filing ↗machine: t87 · r1 · c26 · span 386989–386999 |
| 60 | ANI Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-09 | 0001023024-26-000039 | CEO total compensation as printed in ANI Pharmaceuticals's own proxy. As printed: 10,278,620. Filing ↗machine: r2 · c48 · span 484144–484154 |
| 61 | Travere Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001438533-26-000027 | CEO total compensation as printed in Travere Therapeutics's own proxy. As printed: 8,457,151. Filing ↗machine: span 558514–558523 |
| 62 | Sage Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0000950170-25-058060 | CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793 |
| 63 | Phantom Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001193125-26-144570 | CEO total compensation as printed in Phantom Pharmaceuticals's own proxy. As printed: 6,968,070. Filing ↗machine: r2 · c21 · span 619155–619164 |
| 64 | Akebia Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001517022-26-000034 | CEO total compensation as printed in Akebia Therapeutics's own proxy. As printed: 5,652,339. Filing ↗machine: r3 · c39 · span 516847–516856 |
| 65 | Innoviva, Section 10b CEO total | DEF 14A | 2026-03-24 | 0001140361-26-010912 | CEO total compensation as printed in Innoviva's own proxy. As printed: 5,400,197. Filing ↗machine: t108 · r1 · c25 · span 555478–555487 |
| 66 | Xeris Biopharma Holdings, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001867096-26-000021 | CEO total compensation as printed in Xeris Biopharma Holdings's own proxy. As printed: 5,042,584. Filing ↗machine: r3 · c42 · span 463532–463541 |
| 67 | Rigel Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-03 | 0001034842-26-000023 | CEO total compensation as printed in Rigel Pharmaceuticals's own proxy. As printed: 4,658,805. Filing ↗machine: t120 · r3 · c22 · span 886059–886068 |
| 68 | Y-mAbs Therapeutics, Section 10b CEO total | DEF 14A | 2025-05-30 | 0001558370-25-008299 | CEO total compensation as printed in Y-mAbs Therapeutics's own proxy. As printed: 4,557,590. Filing ↗machine: t100 · r5 · c23 · span 597595–597604 |
| 69 | UroGen Pharma, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001437749-26-014237 | CEO total compensation as printed in UroGen Pharma's own proxy. As printed: 4,310,624. Filing ↗machine: r1 · c29 · span 562926–562935 |
| 70 | Vanda Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026893 | CEO total compensation as printed in Vanda Pharmaceuticals's own proxy. As printed: 3,851,468. Filing ↗machine: span 563696–563705 |
| 71 | Lexicon Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-03-16 | 0001062822-26-000056 | CEO total compensation as printed in Lexicon Pharmaceuticals's own proxy. As printed: 3,553,953. Filing ↗machine: t16 · r2 · c25 · span 400176–400185 |
| 72 | Esperion Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001628280-26-025499 | CEO total compensation as printed in Esperion Therapeutics's own proxy. As printed: 3,535,512. Filing ↗machine: span 423838–423847 |
| 73 | Heron Therapeutics, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-196306 | CEO total compensation as printed in Heron Therapeutics, Inc.'s own proxy. As printed: 3,516,291. Filing ↗machine: span 728212–728221 |
| 74 | Coherus BioSciences, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001104659-26-045251 | CEO total compensation as printed in Coherus BioSciences's own proxy. As printed: 2,736,874. Filing ↗machine: t112 · r5 · c14 · span 540087–540096 |
| 75 | OptiNose, Section 10b CEO total | DEF 14A | 2024-04-26 | 0001494650-24-000047 | CEO total compensation as printed in OptiNose's own proxy. As printed: 2,414,265. Filing ↗machine: r2 · c48 · span 415104–415113 |
| 76 | Collegium Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001628280-26-024063 | CEO total compensation as printed in Collegium Pharmaceuticals's own proxy. As printed: 1,715,846. Filing ↗machine: r2 · c48 · span 779394–779403 |
| 77 | Section 10a, Sage Therapeutics reciprocity | DEF 14A | — | 0000950170-25-058060 | Sage Therapeutics's most recent proxy was read; its disclosed peer group does not include Heron Therapeutics, Inc.. Filing ↗ |
| 78 | Section 10a, Collegium Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-024063 | Collegium Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Heron Therapeutics, Inc.. Filing ↗ |
| 79 | Section 10a, Travere Therapeutics reciprocity | DEF 14A | — | 0001438533-26-000027 | Travere Therapeutics's most recent proxy was read; its disclosed peer group does not include Heron Therapeutics, Inc.. Filing ↗ |
| 80 | Section 10a, Lexicon Pharmaceuticals reciprocity | DEF 14A | — | 0001062822-26-000056 | Lexicon Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Heron Therapeutics, Inc.. Filing ↗ |
| 81 | Section 10a, Vanda Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-026893 | Vanda Pharmaceuticals names Heron Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, Akebia Therapeutics reciprocity | DEF 14A | — | 0001517022-26-000034 | Akebia Therapeutics names Heron Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 83 | Section 10a, Innoviva reciprocity | DEF 14A | — | 0001140361-26-010912 | Innoviva's most recent proxy was read; its disclosed peer group does not include Heron Therapeutics, Inc.. Filing ↗ |
| 84 | Section 10a, Ocular Therapeutics reciprocity | DEF 14A | — | 0001104659-26-053176 | Ocular Therapeutics's most recent proxy was read; its disclosed peer group does not include Heron Therapeutics, Inc.. Filing ↗ |
| 85 | Section 10a, Xeris Biopharma Holdings reciprocity | DEF 14A | — | 0001867096-26-000021 | Xeris Biopharma Holdings's most recent proxy was read; its disclosed peer group does not include Heron Therapeutics, Inc.. Filing ↗ |
| 86 | Section 10a, Harrow reciprocity | DEF 14A | — | 0001493152-26-018912 | Harrow names Heron Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 87 | Section 10a, Y-mAbs Therapeutics reciprocity | DEF 14A | — | 0001558370-25-008299 | Y-mAbs Therapeutics names Heron Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 88 | Section 10a, Rigel Pharmaceuticals reciprocity | DEF 14A | — | 0001034842-26-000023 | Rigel Pharmaceuticals names Heron Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 89 | Section 10a, Coherus BioSciences reciprocity | DEF 14A | — | 0001104659-26-045251 | Coherus BioSciences names Heron Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 90 | Section 10a, UroGen Pharma reciprocity | DEF 14A | — | 0001437749-26-014237 | UroGen Pharma's most recent proxy was read; its disclosed peer group does not include Heron Therapeutics, Inc.. Filing ↗ |
| 91 | Section 10a, ANI Pharmaceuticals reciprocity | DEF 14A | — | 0001023024-26-000039 | ANI Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Heron Therapeutics, Inc.. Filing ↗ |